Frazier Life Sciences Management, L.P. Krystal Biotech, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 688,460 shares of KRYS stock, worth $103 Million. This represents 7.81% of its overall portfolio holdings.
Number of Shares
688,460
Previous 788,460
12.68%
Holding current value
$103 Million
Previous $124 Million
0.49%
% of portfolio
7.81%
Previous 7.41%
Shares
9 transactions
Others Institutions Holding KRYS
# of Institutions
332Shares Held
24.2MCall Options Held
299KPut Options Held
97.6K-
Black Rock Inc. New York, NY3.95MShares$593 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.83MShares$424 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.73MShares$410 Million7.97% of portfolio
-
State Street Corp Boston, MA1.23MShares$184 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA954KShares$143 Million0.03% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.85B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...